Christian Naus discusses his work on 3D glioma models, which could facilitate personalized medicine approaches to one of the brain’s most significant threats.
Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.
A group of researchers from the Dana-Farber Cancer Institute (MA, USA) has conducted the largest clinical study to date of genetic abnormalities in pediatric brain tumors.
This article reviews new vaccination protocols against glioblastoma, as well as new the prospect of novel combination therapies.
Lauren Pulling highlights some of the key trending topics in neurology and neuroscience from 2016, as well as the top read articles of the year – take a look and let us know your thoughts.
In this article, the authors report the case of a patient suffering from a melanoma with multiple brain metastasis, treated with BRAF and MEK double blockade, with impressive and rapid response.
A recent study has identified a potential genetic biomarker, SHOX2, for predicting the survival of patients with diffuse glioma brain tumors.
Researchers have developed novel mini ‘artificial brains’ to model glioma tumor growth: the organoids could soon be used to develop personalized treatment strategies against brain cancers.
In this Special Report, the authors discuss how the versatility of utilizing cancer-targeting alkylphosphocholine analogs may ultimately transform clinical management of primary and metastatic brain tumors.
In this study, the authors identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine.